CureVac präsentiert vorläufige Daten seiner Phase-I-Studie mit dem RNA-basierten Wirkstoff CV8102 zur intratumoralen Anwendung auf der 33. Jahrestagung der Society for Immunotherapy of Cancer
November 07, 2018 07:00 ET
|
CureVac AG
Die Daten umfassen CV8102 als Einzelwirkstoff und in Kombination mit einer Anti-PD1-Therapie TÜBINGEN, Deutschland / BOSTON, USA, Nov. 07, 2018 (GLOBE NEWSWIRE) -- Das biopharmazeutische...
CureVac to Present Preliminary Phase I Data on CV8102, an Intratumoral RNA-based Cancer Therapy, at the Society for Immunotherapy of Cancer’s 33rd Annual Meeting
November 07, 2018 07:00 ET
|
CureVac AG
Data to be presented includes CV8102 as a single agent and in combination with anti-PD1 therapy TÜBINGEN, Germany and BOSTON, Nov. 07, 2018 (GLOBE NEWSWIRE) -- CureVac AG, a fully integrated...
Jounce Therapeutics to Present Two Posters from the JTX-2011 Program at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting
November 02, 2018 13:48 ET
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 02, 2018 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...